Antibiotics/stewardship;
S.1355/H.R.2940, PASTEUR Act of 2023;
Value of prescription drugs;
Issues related to the Vaccine Injury Compensation Program (VICP);
Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization;
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation;
Issues related to HPV vaccine and ACIP recommendations;
Expiring healthcare extenders;
S. 1339, The Pharmacy Benefit Manager Reform Act;
H.R. 4366, the Consolidated Appropriations Act, 2024 (P.L. 118-42);
H.R. 2882, the Further Consolidated Appropriations Act, 2024 (P.L. 118-47);
Issues related to 340b
Value of prescription drugs;
Issues related to Medicare Parts B and D;
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation;
S. 2973, The Modernizing and Ensuring PBM Accountability (MEPA) Act;
H.R. 5378, The Lower Costs, More Transparency Act;
Issues related to Medicaid Drug Rebate Program
Issues related to biosecurity
Duration: February 2, 2015
to
present
General Issues: Health Issues , Medicare/Medicaid , Homeland Security , Budget/Appropriations , Pharmacy
Spending: about $1,830,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2015: House of Representatives, U.S. Senate, White House Office, Office of Science & Technology Policy (OSTP), Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Tracy Spicer Dep. Chief of Staff, Sen. Edward M. Kennedy
Political Director, Sen. Edward M. Kennedy
Legislative Assistant, Sen. Edward M. Kennedy
Special Assistant, Sen. Edward M. Kennedy
Staff Assistant, Sen. Edward M. Kennedy
Amy Tejral Legislative Director, Sen. Ben Nelson
Elizabeth Barnett Legislative Assistant, Sen. Blanche Lincoln
Speechwriter, Sen. Blanche Lincoln
Legislative Correspondent, Sen. Blanche Lincoln
Staff Assistant, Sen. Energy/Natural Resource Cmte
Yvette Fontenot Sr. Legis. Advisor, Sen. Jay Rockefeller
Medicare Specialist, OMB
Prof. Staff, H. Energy & Commerce Committee
Prof. Staff, Sen. Finance Committee
Sr. Policy Director, WH Office of Health Reform
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on April 22.
Original Filing: 301574416.xml
Lobbying Issues
Antibiotics/stewardship;
S.1355/H.R.2940, PASTEUR Act of 2023;
Value of prescription drugs;
Issues related to the Vaccine Injury Compensation Program (VICP);
Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization;
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation;
Issues related to HPV vaccine and ACIP recommendations;
Expiring healthcare extenders;
S. 1339, The Pharmacy Benefit Manager Reform Act;
H.R. 4366, the Consolidated Appropriations Act, 2024 (P.L. 118-42);
H.R. 2882, the Further Consolidated Appropriations Act, 2024 (P.L. 118-47);
Issues related to 340b
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Value of prescription drugs;
Issues related to Medicare Parts B and D;
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation;
S. 2973, The Modernizing and Ensuring PBM Accountability (MEPA) Act;
H.R. 5378, The Lower Costs, More Transparency Act;
Issues related to Medicaid Drug Rebate Program
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosecurity
4th Quarter, 2023
In Q4, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on Jan. 22.
Original Filing: 301539464.xml
Lobbying Issues
Antibiotics/stewardship;
S.1355/H.R.2940, PASTEUR Act of 2023;
Value of prescription drugs;
Issues related to the Vaccine Injury Compensation Program (VICP);
Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization;
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation;
Issues related to S. 1844, Animal Drug and Animal Generic Drug User Fee Amendments of 2023;
Issues related to HPV vaccine and ACIP recommendations;
Expiring healthcare extenders;
S. 1339, The Pharmacy Benefit Manager Reform Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Value of prescription drugs;
Issues related to Medicare Parts B and D;
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation;
Senate Finance Committees Better Mental Health Care, Lower Cost Drugs and Extenders Act (Discussion Draft);
S. 2973, The Modernizing and Ensuring PBM Accountability (MEPA) Act;
H.R. 5378, The Lower Costs, More Transparency Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on Oct. 20, 2023.
Original Filing: 301511225.xml
Lobbying Issues
Antibiotics/stewardship;
S.1355/H.R.2940, PASTEUR Act of 2023;
Value of prescription drugs;
Issues related to the Vaccine Injury Compensation Program (VICP);
Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization;
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation;
Issues related to S. 1844, Animal Drug and Animal Generic Drug User Fee Amendments of 2023;
Issues related to HPV vaccine and ACIP recommendations
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Value of prescription drugs;
Issues related to Medicare Parts B and D;
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation
2nd Quarter, 2023
In Q2, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on July 19, 2023.
Original Filing: 301484069.xml
Lobbying Issues
Antibiotics/stewardship;
S.1355/H.R.2940, PASTEUR Act of 2023;
Value of prescription drugs;
Issues related to the Vaccine Injury Compensation Fund (VICF);
Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization;
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Value of prescription drugs;
Issues related to Medicare Parts B and D;
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2023
In Q1, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on April 20, 2023.
Original Filing: 301464397.xml
Lobbying Issues
Antibiotics/stewardship;
Value of prescription drugs;
Issues related to the Vaccine Injury Compensation Program
Issues related to Vaccine Injury Compensation Fund (VICF);
Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization;
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation;
ACIP recommendations related to pneumococcal vaccines;
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
Value of prescription drugs;
Issues related to Medicare Parts B and D
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2022
In Q4, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on Jan. 20, 2023.
Original Filing: 301439773.xml
Lobbying Issues
Inflation Reduction Act of 2022 (PL 117-169) implementation - creating Medicare negotiation of drugs, creating a new inflation rebate under Medicare, limiting insulin copays to $35/month, capping Medicare Part D premium growth, expanding premium and co-pay assistance on prescription drugs for low-income individuals, and capping Medicare out of pocket costs at $2,000 per year, and preventing commercial spillover of maximum fair price into markets beyond Medicare;
Consolidated Appropriations Act, 2023 (PL 117-328)- allowing new vaccines to be added to the Vaccine Injury Compensation Fund (VICF), preserving coverage and access to Part D products under EUA;
Antibiotics/stewardship;
Value of prescription drugs;
S. 2076/H.R. 3932, PASTEUR Act of 2021;
ACIP recommendations related to pneumococcal vaccines;
S. 3700/H.R. 6833, Affordable Insulin Now Act;
Issues related to reauthorization of FDA user fee bills (H.R.7667, Food and Drug Amendments of 2022; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including accelerated approval and reimportation;
Issues related to the Public Health Emergency;
Issues related to the White House Cancer Moonshot initiative;
S. 2706/H.R. 5030, DIVERSE Trials Act;
Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act;
Executive Order Directing HHS to Explore Additional Actions to Lower Prescription Drug Costs
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
S.2076/H.R.3932, PASTEUR Act of 2021;
Value of prescription drugs;
Issues related to Medicare Parts B and D;
Issues related to Vaccine Injury Compensation Fund (VICF);
Issues related to coverage of EUA products in Part D
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2022
In Q3, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on Oct. 20, 2022.
Original Filing: 301413804.xml
Lobbying Issues
Issues related to H.R. 5376, Inflation Reduction Act of 2022 (now PL 117-169) and implementation;
Issues related to the Continuing Resolution, H.R. 6833;
Antibiotics/stewardship;
Value of prescription drugs;
H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act (DISARM Act);
S. 2076/H.R. 3932, PASTEUR Act of 2021;
ACIP recommendations related to pneumococcal vaccines;
S. 3700/H.R. 6833, Affordable Insulin Now Act;
Issues related to reauthorization of FDA user fee bills (H.R.7667, Food and Drug Amendments of 2022; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including accelerated approval and reimportation;
Issues related to the Public Health Emergency;
H.R. 5585, The Advanced Research Project Agency-Health (ARPA-H) Act;
Issues related to the White House Cancer Moonshot initiative;
S. 2706/H.R. 5030, DIVERSE Trials Act;
Issues related to the FY 2023 Presidents Budget;
Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act (DISARM Act);
S.2076/H.R.3932, PASTEUR Act of 2021;
Value of prescription drugs;
Issues related to Medicare Parts B and D
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2022
In Q2, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on July 20, 2022.
Original Filing: 301393445.xml
Lobbying Issues
Antibiotics/stewardship;
Value of prescription drugs;
H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act (DISARM Act);
S. 2076/H.R. 3932, PASTEUR Act of 2021;
H.R. 5376, Build Back Better Act;
Monitor possible healthcare policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, addressing Medicaid coverage gap, expanding home and community based services, prescription drug reform;
ACIP recommendations related to pneumococcal vaccines;
Cancer Moonshot;
S. 3700/H.R. 6833, Affordable Insulin Now Act;
Issues related to reauthorization of FDA user fee bills (H.R.7667, Food and Drug Amendments of 2022; S. 4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including accelerated approval and reimportation;
Issues related to the Public Health Emergency;
H.R. 5585, The Advanced Research Project Agency-Health (ARPA-H) Act;
Issues related to the White House Cancer Moonshot initiative;
S. 2706/H.R. 5030, DIVERSE Trials Act;
Issues related to the FY 2023 Presidents Budget;
Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act;
Senate Finance Committee bipartisan Discussion Draft: Ensuring Access to Telemental Health Services;
Senate Finance Committee bipartisan Discussion Draft: Improving Access to Physical and Mental Health Care for Children and Youth under Medicaid and CHIP;
Bipartisan Safer Communities Act, P.L. 117-159, specifically policy related to access to mental health services for youth and families through Medicaid and CHIP and telehealth;
H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act (DISARM Act);
S.2076/H.R.3932, PASTEUR Act of 2021;
Value of prescription drugs;
Issues related to Medicare Parts B and D;
Implementation of American Rescue Plan Act of 2021 (PL 117-2)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2022
In Q1, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on April 20, 2022.
Original Filing: 301371363.xml
Lobbying Issues
Antibiotics/stewardship;
Value of prescription drugs;
H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act (DISARM Act);
S. 2076/H.R. 3932, PASTEUR Act of 2021;
Implementation of American Rescue Plan Act of 2021 (PL 117-2);
Vaccine hesitancy issues;
H.R. 5376, Build Back Better Act;
Monitor possible healthcare policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, addressing Medicaid coverage gap, expanding home and community based services, prescription drug reform;
ACIP recommendations related to pneumococcal vaccines;
Cancer Moonshot;
Infrastructure Investment and Jobs Act (PL 117-58) - issues related to rebate rule delay, repurposed Provider Relief Funds, Medicare savings from single source vial size drug policy and extension of mandatory sequester);
Consolidated Appropriations Act, 2022 (PL 117-103);
S. 3700/H.R. 6833, Affordable Insulin Now Act;
Issues related to reauthorization of the FDA user fee bills;
Issues related to the Public Health Emergency;
H.R. 5585, The Advanced Research Project Agency-Health (ARPA-H) Act;
Issues related to the White House Cancer Moonshot initiative;
Issues related to accelerated approval;
S. 2706/H.R. 5030, DIVERSE Trials Act;
Issues related to the FY 2023 Presidents Budget
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act (DISARM Act);
S.2076/H.R.3932, PASTEUR Act of 2021;
Value of prescription drugs;
Issues related to Medicare Parts B and D;
Implementation of American Rescue Plan Act of 2021 (PL 117-2)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2021
In Q4, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on Jan. 19, 2022.
Original Filing: 301330129.xml
Lobbying Issues
Antibiotics/stewardship;
Value of prescription drugs;
H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act (DISARM Act);
S. 2076/H.R. 3932, PASTEUR Act of 2021;
Implementation of American Rescue Plan Act of 2021 (PL 117-2);
Vaccine hesitancy issues;
H.R. 5376, Build Back Better Act;
Monitor possible healthcare policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, adding Medicare enhancements/supplemental benefits (hearing, dental, vision), addressing Medicaid coverage gap, expanding home and community based services, prescription drug reform;
ACIP recommendations related to pneumococcal vaccines;
Cancer Moonshot;
PL 117-58 - Infrastructure Investment and Jobs Act (BIF) - issues related to rebate rule delay, repurposed Provider Relief Funds, Medicare savings from single source vial size drug policy and extension of mandatory sequester)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act (DISARM Act);
S.2076/H.R.3932, PASTEUR Act of 2021;
Value of prescription drugs;
Issues related to Medicare Parts B and D;
Implementation of American Rescue Plan Act of 2021 (PL 117-2);
Proposed repeal of the CMS Rule on Most Favored Nation Model;
Delay of the Medicare Part D Rebate Rule;
PL-117-71 Protecting Medicare and American Families from Sequester Cuts Act - specifically: 6 months relief from 2% Medicare sequester, 4% statutory Pay-As-You-Go Act, 1 year relief of physician conversion factor cuts, 1 year delay of clinical lab (PAMA) cuts, delay of radiation oncology demo
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2021
In Q3, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on Oct. 20, 2021.
Original Filing: 301313812.xml
Lobbying Issues
Antibiotics/stewardship;
Value of prescription drugs;
H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act (DISARM Act);
S. 2076/H.R. 3932, PASTEUR Act of 2021;
Implementation of American Rescue Plan Act of 2021 (P.L. 117-2);
Vaccine hesitancy issues;
H.R. 5376, Build Back Better Act;
Monitor possible healthcare policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, adding Medicare enhancements/supplemental benefits (hearing, dental, vision), addressing Medicaid coverage gap, expanding home and community based services, prescription drug reform
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act (DISARM Act);
S.2076/H.R.3932, PASTEUR Act of 2021;
Value of prescription drugs;
Issues related to Medicare Parts B and D;
Senate Finance Committee Prescription Drug Pricing Reform Principles;
Implementation of American Rescue Plan Act of 2021 (PL 117-2);
Proposed repeal of the CMS Rule on Most Favored Nation Model;
Delay of the Medicare Part D Rebate Rule
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2021
In Q2, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on July 20, 2021.
Original Filing: 301290070.xml
Lobbying Issues
Antibiotics/stewardship;
Value of prescription drugs;
Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act (DISARM Act);
Implementation of American Rescue Plan Act of 2021 (P.L. 117-2);
Vaccine hesitancy issues
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act (DISARM Act);
Value of prescription drugs;
Issues related to Medicare Parts B and D;
Senate Finance Committee Prescription Drug Pricing Reform Principles;
Implementation of American Rescue Plan Act of 2021 (PL 117-2)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2021
In Q1, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on April 20, 2021.
Original Filing: 301262438.xml
Lobbying Issues
Antibiotics/stewardship;
Value of prescription drugs;
Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act (DISARM Act)
H.R. 1319, American Rescue Plan Act of 2021 (P.L. 117-2)
Continued monitoring of Consolidated Appropriations Act, 2021 (P.L. 116-260)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act (DISARM Act);
Value of prescription drugs;
Issues related to Medicare Parts B and D;
Medicaid AMP (Average Manufacturer Price) cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L. 117-2);
Continued monitoring of Consolidated Appropriations Act, 2021 (P.L. 116-260)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2020
In Q4, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on Jan. 21, 2021.
Original Filing: 301244223.xml
Lobbying Issues
Antibiotics/stewardship;
Value of prescription drugs;
S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019;
H.R. 4100, DISARM Act of 2019;
S. 2543, Prescription Drug Pricing Reduction Act of 2019;
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act;
H.R. 6800, The HEROES Act;
H.R. 925, The HEROES Act;
H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act; Public Law 116-159;
Issues related to vaccines;
H.R. 133/P.L. 116-260, Consolidated Appropriations Act, 2021
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019;
Value of prescription drugs;
Issues related to Medicare Parts B and D;
Biosimilars policies;
Medicaid AMP (Average Manufacturer Price) cap;
S. 2543, Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2020
In Q3, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on Oct. 20, 2020.
Original Filing: 301223125.xml
Lobbying Issues
Antibiotics/stewardship;
Value of prescription drugs;
Issues related to Title X and women's preventative health services;
S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019;
H.R. 4100, DISARM Act of 2019;
S. 2543, Prescription Drug Pricing Reduction Act of 2019;
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act;
H.R. 6800, The HEROES Act;
H.R. 925, The HEROES Act;
H.R. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act; Public Law 116-159;
Issues related to vaccines
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019;
Value of prescription drugs;
Issues related to Medicare Parts B and D;
Biosimilars policies;
Medicaid AMP (Average Manufacturer Price) cap;
S. 2543, Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2020
In Q2, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on July 20, 2020.
Original Filing: 301201443.xml
Lobbying Issues
Antibiotics/stewardship;
Value of prescription drugs;
Issues related to Title X and women's preventative health services;
S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019;
H.R. 4100, DISARM Act of 2019;
S. 2543, Prescription Drug Pricing Reduction Act of 2019;
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act;
H.R. 6800, HEROES Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019;
Value of prescription drugs;
Issues related to Medicare Parts B and D;
Biosimilars policies;
Medicaid AMP (Average Manufacturer Price) cap;
S. 2543, Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2020
In Q1, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on April 17, 2020.
Original Filing: 301170218.xml
Lobbying Issues
Antibiotics/stewardship;
Value of prescription drugs;
Issues related to Title X and women's preventative health services;
S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019;
H.R. 4100, DISARM Act of 2019;
H.R. 748 (Public Law 116-136), CARES Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019;
Value of prescription drugs;
Issues related to Medicare Parts B and D;
Biosimilars policies;
Medicaid AMP (Average Manufacturer Price) cap;
S. 2543, Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2019
In Q4, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on Jan. 18, 2020.
Original Filing: 301120966.xml
Lobbying Issues
Antibiotics/stewardship;
Value of prescription drugs;
Issues related to Title X and women's preventative health services;
S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019;
H.R. 4100, DISARM Act of 2019;
H.R. 1865, Consolidated Domestic and International Assistance Bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019;
Value of prescription drugs;
Issues related to Medicare Parts B and D;
Biosimilars policies;
Medicaid AMP (Average Manufacturer Price) cap;
S. 2543, Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2019
In Q3, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on Oct. 17, 2019.
Original Filing: 301068909.xml
Lobbying Issues
Antibiotics/stewardship;
Value of prescription drugs;
Issues related to Title X and women's preventative health services;
S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019;
H.R. 4100, DISARM Act of 2019
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019;
Value of prescription drugs;
Issues related to Medicare Parts B and D;
Biosimilars policies;
Medicaid AMP (Average Manufacturer Price) cap
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2019
In Q2, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on July 19, 2019.
Original Filing: 301052695.xml
Lobbying Issues
Antibiotics/stewardship;
Value of prescription drugs;
Issues related to Title X and women's preventative health services
S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019;
Value of prescription drugs;
Issues related to Medicare Parts B and D;
Biosimilars policies;
Medicaid AMP (Average Manufacturer Price) cap
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2019
In Q1, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on April 19, 2019.
Original Filing: 301031156.xml
Lobbying Issues
Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization;
Antibiotics/stewardship;
Value of prescription drugs;
Issues related to Title X and women's preventative health services
Discussions related to the reintroduction of S. 3787, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act from 115th Congress
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
Value of prescription drugs;
Discussions related to the reintroduction of S. 3787, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act from 115th Congress
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2018
In Q4, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on Jan. 21, 2019.
Original Filing: 301012174.xml
Lobbying Issues
Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization;
Antibiotics/stewardship;
Value of prescription drugs;
Monitor opioids legislation;
Monitor 2019 Labor HHS appropriations legislation for impact on cervical cancer testing;
S. 3787, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2018
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
Value of prescription drugs;
S. 3787, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2018
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2018
In Q3, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on Oct. 19, 2018.
Original Filing: 300990459.xml
Lobbying Issues
PABA reauthorization;
Antibiotics/stewardship;
Value of prescription drugs;
Monitor opioids legislation;
Monitor 2019 Labor HHS appropriations legislation for impact on cervical cancer testing
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
Value of prescription drugs
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2018
In Q2, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on July 19, 2018.
Original Filing: 300970591.xml
Lobbying Issues
PABA reauthorization;
Antibiotics/stewardship;
Value of prescription drugs
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
Value of prescription drugs
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2018
In Q1, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on April 19, 2018.
Original Filing: 300951141.xml
Lobbying Issues
CHIP reauthorization and Medicare extenders;
PABA reauthorization;
Antibiotics/stewardship;
Value of prescription drugs;
Issues related to healthcare discussions/offsets for budget deal and healthcare extender policies;
H.R. 1892 / PL 115-123, Bipartisan Budget Act of 2018;
H.R. 1625 / PL 115-141, Omnibus/Consolidated Appropriations Act of 2018
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
Value of prescription drugs
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2017
In Q4, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on Jan. 22, 2018.
Original Filing: 300936527.xml
Lobbying Issues
CHIP reauthorization and Medicare extenders;
Issues related to year-end healthcare discussions/offsets for budget deal and healthcare extender policies;
PABA reauthorization;
Antibiotics/stewardship;
Value of prescription drugs
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
Value of prescription drugs
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2017
In Q3, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on Oct. 17, 2017.
Original Filing: 300905490.xml
Lobbying Issues
H.R. 1628, American Health Care Act of 2017;
Better Care Reconciliation Act;
PDUFA VI reauthorization and prescription drug policies;
Graham-Cassidy healthcare reconciliation bill;
CHIP reauthorization
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
Value of prescription drugs
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2017
In Q2, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on July 20, 2017.
Original Filing: 300896021.xml
Lobbying Issues
HPV vaccine;
H.R. 1628, American Health Care Act of 2017;
Better Care Reconciliation Act discussion draft;
PDUFA VI reauthorization & prescription drug policies.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
Value of prescription drugs
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2017
In Q1, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on April 20, 2017.
Original Filing: 300875085.xml
Lobbying Issues
S. Con. Res. 3 (Senate Budget Resolution 2017) - prescription drug policies
Lobbying Issues
HPV vaccine;
H.R. 1628, American Health Care Act of 2017
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
Value of prescription drugs
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2016
In Q4, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on Jan. 23, 2017.
Original Filing: 300856333.xml
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
Value of prescription drugs
Lobbying Issues
HPV vaccine;
H.R. 5325, Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2017, and Zika Response and Preparedness Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on Oct. 20, 2016.
Original Filing: 300837085.xml
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
Value of prescription drugs
Lobbying Issues
HPV vaccine;
H.R. 5325, Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2017, and Zika Response and Preparedness Act
2nd Quarter, 2016
In Q2, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on July 20, 2016.
Original Filing: 300819014.xml
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Antibiotics/stewardship;
Value of prescription drugs
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on April 20, 2016.
Original Filing: 300799820.xml
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
Issues relating to 340b Drug Pricing Program;
Antibiotics/stewardship;
Value of prescription drugs
Lobbying Issues
HPV vaccine;
Moonshot initiative for eliminating cancer
4th Quarter, 2015
In Q4, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on Jan. 20, 2016.
Original Filing: 300779021.xml
Lobbying Issues
issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
H.R. 512, DISARM Act of 2015 (Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2015);
issues relating to 340b Drug Pricing Program;
antibiotics/stewardship
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2015
In Q3, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on Oct. 20, 2015.
Original Filing: 300763216.xml
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
H.R. 512, DISARM Act of 2015 (Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2015);
H.R. 6, 21st Century Cures Act;
issues relating to 340b Drug Pricing Program
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2015
In Q2, Avenue Solutions lobbied for Merck & Co. Inc. , earning $50,000. The report was filed on July 17, 2015.
Original Filing: 300738096.xml
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
H.R. 512, DISARM Act of 2015 (Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2015);
H.R. 6, 21st Century Cures Act
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2015
In Q1, Avenue Solutions lobbied for Merck & Co. Inc. , earning $30,000. The report was filed on April 20, 2015.
Original Filing: 300724500.xml
Lobbying Issues
Issues relating to the further development of antibiotics and antimicrobials for serious and unmet medical needs;
H.R. 512, DISARM Act of 2015 (Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2015)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Medicaid
1st Quarter, 2015
Avenue Solutions filed a lobbying registration on Feb. 8, 2015 to represent Merck & Co. Inc., effective Feb. 2, 2015.
Original Filing: 300710631.xml
Issue(s) they said they’d lobby about: Issues related to the further development of antibiotics and antimicrobials for serious and unmet medical needs .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...